Paris, France – June 12, 2008 -- Biogen Idec will present data on baminercept alfa (BG9924, LTßR-Ig), the first dual-mechanism, lymphotoxin-ß; (LT-ß;) and LIGHT pathway inhibitor in development for ...

Biogen and IDEC Pharmaceuticals, two rivals racing to develop drugs for cancer and other diseases, announced plans Monday to merge and create the No. 3 biotechnology company, the latest of a string of ...

During the early days of the biotechnology industry, there were several bellwether companies that analysts and other industry observers kept an eye on to get a sense of the biobusiness world’s health ...

NEW ORLEANS, MAY 18, 2004 – Elan Corporation, plc and Biogen Idec announced that in a Phase III maintenance study, ANTEGREN® (natalizumab) maintained clinical response and remission rates throughout ...

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret. By Walt Bogdanich and Carson Kessler The drug, Kisunla, made by ...

Idec Pharmaceuticals Corp. and Biogen Inc. announced yesterday that they would merge in a $6.8 billion deal that will create a powerhouse in the biotechnology industry, with the new company earning ...

The search is on for a new head. Mullen rose through the ranks at Biogen after coming on as director of facilities and engineering in 1989. He became head of Biogen in 2000, and kept that post when ...

LOS ANGELES, May 29 (Reuters) - Biogen Idec on Tuesday said its board has authorized a $3 billion share repurchase through a modified "Dutch Auction" tender offer of about 57 million shares, or 16 ...

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The table below provides a concise overview of ...

Ratings for Biogen (NASDAQ:BIIB) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their ...